Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside

Area of Science:

• Cardiovascular Science
• Hematology
• Pharmacology

Background:

• Atherosclerotic cardiovascular disease (ASCVD) is a primary global cause of mortality.
• Significant aspects of ASCVD pathophysiology remain poorly understood.
• Hematological factors are increasingly recognized for their role in ASCVD development and prognosis.

Purpose of the Study:

• To comprehensively review the role of emerging hematological targets in ASCVD.
• To examine current and novel therapeutic strategies for ASCVD targeting these factors.

Main Methods:

• Literature review of scientific articles.
• Synthesis of information on hematological targets and antiatherosclerotic therapies.
• Analysis of the interplay between pathophysiology, targets, and treatments.

Main Results:

• Identified key hematological targets: soluble cytokines, leukocytes, red blood cells, hemostatic factors, platelets, and bone-marrow vascular progenitors.
• Discussed modulation of these targets by pharmacotherapy, novel drugs, and progenitor cell therapy.
• Highlighted the potential of these factors in understanding and treating ASCVD.

Conclusions:

• Hematological targets offer promising avenues for ASCVD management.
• Therapeutic strategies targeting these factors, including novel drugs and cell therapies, show potential.
• Further research into these targets is crucial for advancing antiatherosclerotic treatments.